查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1464900

比伐盧定市場：按劑型、應用和最終用途 - 2024-2030 年全球預測

Bivalirudin Market by Dosage Form (Injection, Powder), Application (Angioplasty, Heparin-induced Thrombocytopenia, Percutaneous Coronary Intervention), End-Use - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年比伐盧定市場規模為12.3億美元，預計2024年將達13.1億美元，2030年將達到18.7億美元，複合年成長率為6.13%。

比伐盧定是一種主要用作抗凝血劑的藥物，有助於防止血栓形成。比伐盧定屬於一類稱為直接凝血酶抑制劑的藥物，可減少血管中形成血栓的機會。這在血栓可能導致嚴重健康問題（例如心臟病、中風以及動脈和靜脈阻塞）的情況下尤其重要。世界各地心臟病的增加增加了對有效治療方法，包括血管成形術，比伐盧定在其中發揮關鍵作用。此外，製劑創新在提高比伐盧定療效和減少副作用方面具有巨大潛力，從而催生了更有效、更安全的抗凝血劑選擇。然而，比伐盧定的高成本和相關的醫療程序限制了其對更廣泛患者群體的可用性。此外，替代抗凝血劑和新藥進入市場可能會對最終用戶採用比伐盧定帶來挑戰。然而，醫療基礎設施投資和支出的增加以及心血管疾病負擔的增加正在推動先進藥物的採用。隨著研究繼續探索比伐盧定與其他藥物的組合，我們期望在未來幾年開拓新的治療領域並擴大比伐盧定的使用。

主要市場統計
基準年[2023] 12.3億美元
預測年份 [2024] 13.1億美元
預測年份 [2030] 18.7億美元
複合年成長率（%） 6.13%

型態: 比伐盧定注射液經常在外科手術過程中使用。

注射用比伐盧定主要用於急性期，例如外科手術期間或醫院內，並提供即時抗凝血作用。注射劑起效迅速，這對於突發和高風險的凝血情況至關重要。粉末狀比伐盧定通常是首選，因為與預混合料相比，彈性且保存期限更長。這種劑型對於非緊急情況或需要根據個別患者需求精確調整劑量的客製化給藥方案是有利的。注射劑在緊急性和即時使用方面的便利性是無與倫比的，特別是在重症加護和手術環境中。另一方面，粉末製劑具有在使用前立即製備藥物、滿足特定劑量需求並消除浪費的多功能性和經濟性。

最終用途：比伐盧定在門診手術中心的新用途

門診手術中心 (ASC) 越來越成為不需要住宿的小型手術的首選。比伐盧定在 ASC 中的使用主要圍繞其最低監測要求、快速作用和短半衰期，這使其適合門診病人環境。由於比伐盧定在急診環境中的廣泛用途，醫院和診所是比伐盧定的主要使用者。在醫院和診所，比伐盧定用於更廣泛和侵入性的心血管手術，其快速起效和可逆性使其非常有益。專科診所，特別是循環系統科診所，經常在接受診斷性心導管插入術和其他非手術干預的患者中使用比伐盧定。

區域洞察

由於心臟病的高發病率和發達的醫療基礎設施，美洲對比伐盧定的需求正在增加。客戶的購買行為傾向於信任經過臨床驗證的藥物，其中比伐盧定因其可有效減少出血併發症而受到青睞。歐洲國家對比伐盧定採取了統一的方法，該方法深受歐盟 (EU) 法規和醫療保健指南的影響。採用情況因每個國家的醫療保健系統、可用性和報銷政策而異。在歐盟（EU），由於人口老化和心血管疾病的增加，對比伐盧定的需求正在穩步增加。在中東和非洲，由於醫療保健投資的增加以及與國際醫療機構的合作，比伐盧定市場正在興起。由於政府的醫療改革措施和對醫院基礎設施的投資，亞太地區是比伐盧定的一個充滿活力的市場。

FPNV定位矩陣

FPNV定位矩陣對於評估比伐盧定市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估，供應商被分為四個成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對比伐盧定市場供應商的現狀進行深入而詳細的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻，以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外，該分析還提供了對該行業競爭特徵的寶貴見解，包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。這種詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略，從而在市場上獲得競爭優勢。

本報告對以下幾個方面提供了寶貴的見解：

1. 市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2. 市場開拓：我們深入研究利潤豐厚的新興市場，並分析其在成熟細分市場的滲透率。

3. 市場多元化：提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。

4. 競爭評估和情報：對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況和製造能力進行全面評估。

5. 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告解決了以下關鍵問題：

1. 比伐盧定市場規模及預測是多少？

2.比伐盧定市場預測期間需要考慮投資的產品、細分市場、應用和領域有哪些？

3.比伐盧定市場的技術趨勢和法規結構是什麼？

4.比伐盧定市場主要廠商的市場佔有率為何？

5. 進入比伐盧定市場合適的型態和策略手段是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 對治療心血管疾病的有效抗凝血劑的需求日益成長。
      • 增加消費者在藥品和藥品改善的支出
    • 抑制因素
      • 與其他選擇相比，比伐盧定價格昂貴
    • 機會
      • 即用型比伐盧定組合藥物的開發
      • 新產品持續獲得政府核准
    • 任務
      • 與使用比伐盧定相關的風險和併發症
  • 市場區隔分析
    • 劑型：比伐盧定通常在手術期間以注射劑的形式使用。
    • 最終用途：比伐盧定在門診手術中心的新用途
  • 市場擾動分析
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 價格分析
  • 技術分析
  • 專利分析
  • 貿易分析
  • 法規結構分析

第6章 比伐盧定市場（依劑型分類）

  • 注射
  • 粉末

第7章 比伐盧定市場：依應用分類

  • 血管成形術
  • 肝素誘發的血小板減少性疾病
  • 經皮冠狀動脈介入治療

第8章比伐盧定市場：依最終用途

  • 門診手術中心
  • 醫院/診所
  • 專科診所

第9章 北美、南美洲比伐盧定市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章 亞太地區比伐盧定市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲、中東和非洲比伐盧定市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭場景分析
    • Avenacy 推出非專利藥比伐盧定注射液，擴大了美國抗凝血藥物的選擇
    • Endo International推出即用型比伐盧定注射液以提高臨床效率
    • 遠藤國際宣佈建立戰略聯盟，分銷美國即用型比伐盧定注射液
  • 戰略分析和建議

第13章競爭產品組合

  • 主要企業簡介
  • 主要產品系列
Product Code: MRR-7A22CB0E5BB3

[189 Pages Report] The Bivalirudin Market size was estimated at USD 1.23 billion in 2023 and expected to reach USD 1.31 billion in 2024, at a CAGR 6.13% to reach USD 1.87 billion by 2030.

Bivalirudin is a medication primarily used as an anticoagulant, which helps prevent blood clot formation. Bivalirudin belongs to a class of drugs known as direct thrombin inhibitors, which reduces the likelihood of clots forming in the blood vessels. This is especially important in situations where blood clots can lead to severe health issues such as heart attacks, strokes, or blockages in the arteries or veins. An increase in the global incidence of heart diseases has led to a higher need for effective treatment options, including angioplasty, where bivalirudin plays a critical role. Moreover, the significant potential for innovation in formulating bivalirudin to enhance its efficacy and reduce side effects led to more effective and safer anticoagulant options. However, the high cost of bivalirudin and related medical procedures limit its accessibility to a broader patient base. In addition, the presence of alternative anticoagulants and new drugs entering the market may challenge bivalirudin adoption among end-users. Nevertheless, an increase in healthcare infrastructure investments and spending, along with a rising burden of cardiovascular diseases, is improving the adoption of advanced drug medications. The ongoing exploration of bivalirudin in combination with other drugs is expected to open new therapeutic areas and extend the application of bivalirudin in the coming years.

KEY MARKET STATISTICS
Base Year [2023] USD 1.23 billion
Estimated Year [2024] USD 1.31 billion
Forecast Year [2030] USD 1.87 billion
CAGR (%) 6.13%

Dosage Form: Significant usage of bivalirudin in injectable form during surgical procedures

The injectable form of bivalirudin is primarily used in acute settings, such as during surgical procedures or in hospitals, to provide immediate anticoagulation effects. Injection form is beneficial for rapid onset of action, which is crucial for sudden, high-risk clotting conditions. The powder form of bivalirudin offers flexibility in dosing and is often preferred for its longer shelf-life compared to premixed solutions. This form is advantageous in less urgent scenarios or for tailored dosing regimens, where precise adjustments in dosage are required to meet patients' individual needs. The injectable form is unmatched in urgency and convenience for immediate use, especially in critical care and surgical settings. Meanwhile, the powder form offers versatility and economy for situations allowing for the preparation of the drug just before use, catering to specific dosage needs, and reducing wastage.

End-Use: Emerging usage of bivalirudin in ambulatory surgical centers

Ambulatory surgical centers (ASCs) have increasingly become preferred for minor surgical procedures that don't require an overnight stay. The use of bivalirudin in ASCs primarily revolves around its minimal monitoring requirements, quick action, and shorter half-life, which makes it suitable for outpatient settings. Hospitals & clinics are the primary users of bivalirudin, given the wide range of applications in acute care settings. Hospitals and clinics use bivalirudin for more extensive and invasive cardiovascular procedures, where its quick onset and reversibility are highly beneficial. Specialty clinics, particularly those focused on cardiology, often utilize bivalirudin for patients undergoing diagnostic cardiac catheterization or other non-surgical interventions.

Regional Insights

The high prevalence of heart diseases and the advanced healthcare infrastructure stimulate the need for bivalirudin in the Americas. Customer purchasing behavior leans towards trust in clinically proven medications, with bivalirudin being preferred for its efficiency in reducing bleeding complications. European countries showcase a uniform approach towards Bivalirudin, which has been greatly influenced by European Union (EU) regulations and healthcare guidelines. The adoption varies with national healthcare systems, availability, and reimbursement policies. The growing aging population and an increase in cardiovascular diseases underscore a steady need for bivalirudin in the European Union (EU). In the Middle East and Africa, the market for Bivalirudin is emerging due to increasing investments in healthcare and collaborations with international health organizations. The Asia Pacific region represents a dynamic market for bivalirudin due to the government's push towards healthcare reform and investment in hospital infrastructure.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Bivalirudin Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Bivalirudin Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Bivalirudin Market, highlighting leading vendors and their innovative profiles. These include Apotex Inc., Aurobindo Pharma, Avenacy, Inc., Baxter International, Cayman Chemical, Cipla Limited, Dr. Reddy's Laboratories, Endo International plc, Eugia US LLC, Fresenius Kabi, Meitheal Pharmaceuticals, Inc., Merck KGaA, Midas Pharma GmbH, Pfizer Inc., Teva Pharmaceutical Industries Ltd., and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Bivalirudin Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Dosage Form
    • Injection
    • Powder
  • Application
    • Angioplasty
    • Heparin-induced Thrombocytopenia
    • Percutaneous Coronary Intervention
  • End-Use
    • Ambulatory Surgical Centers
    • Hospitals & Clinics
    • Specialty Clinics
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Bivalirudin Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Bivalirudin Market?

3. What are the technology trends and regulatory frameworks in the Bivalirudin Market?

4. What is the market share of the leading vendors in the Bivalirudin Market?

5. Which modes and strategic moves are suitable for entering the Bivalirudin Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing need for effective anticoagulants to treat cardiovascular disorders
      • 5.1.1.2. Growing consumer expenditure for improved drug and medications
    • 5.1.2. Restraints
      • 5.1.2.1. Expensive nature of bivalirudin compared to the alternatives
    • 5.1.3. Opportunities
      • 5.1.3.1. Emerging development of ready-to-use bivalirudin formulations
      • 5.1.3.2. Ongoing government approvals for new products
    • 5.1.4. Challenges
      • 5.1.4.1. Risks and complexities associated with use of bivalirudin
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Dosage Form: Significant usage of bivalirudin in injectable form during surgical procedures
    • 5.2.2. End-Use: Emerging usage of bivalirudin in ambulatory surgical centers
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Bivalirudin Market, by Dosage Form

  • 6.1. Introduction
  • 6.2. Injection
  • 6.3. Powder

7. Bivalirudin Market, by Application

  • 7.1. Introduction
  • 7.2. Angioplasty
  • 7.3. Heparin-induced Thrombocytopenia
  • 7.4. Percutaneous Coronary Intervention

8. Bivalirudin Market, by End-Use

  • 8.1. Introduction
  • 8.2. Ambulatory Surgical Centers
  • 8.3. Hospitals & Clinics
  • 8.4. Specialty Clinics

9. Americas Bivalirudin Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Bivalirudin Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Bivalirudin Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Avenacy Introduces Generic Bivalirudin Injection, Expanding Anticoagulant Options in the U.S.
    • 12.3.2. Endo International Launches Ready-to-Use Bivalirudin Injection Enhancing Clinical Efficiency
    • 12.3.3. Endo International Announces Strategic Partnership for U.S. Distribution of Ready-to-Use Bivalirudin Injection
  • 12.4. Strategy Analysis & Recommendation

13. Competitive Portfolio

  • 13.1. Key Company Profiles
  • 13.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. BIVALIRUDIN MARKET RESEARCH PROCESS
  • FIGURE 2. BIVALIRUDIN MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BIVALIRUDIN MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BIVALIRUDIN MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL BIVALIRUDIN MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. BIVALIRUDIN MARKET DYNAMICS
  • FIGURE 7. GLOBAL BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL BIVALIRUDIN MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL BIVALIRUDIN MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS BIVALIRUDIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS BIVALIRUDIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES BIVALIRUDIN MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES BIVALIRUDIN MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC BIVALIRUDIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC BIVALIRUDIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA BIVALIRUDIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA BIVALIRUDIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. BIVALIRUDIN MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 22. BIVALIRUDIN MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BIVALIRUDIN MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BIVALIRUDIN MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL BIVALIRUDIN MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL BIVALIRUDIN MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL BIVALIRUDIN MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL BIVALIRUDIN MARKET SIZE, BY INJECTION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL BIVALIRUDIN MARKET SIZE, BY INJECTION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL BIVALIRUDIN MARKET SIZE, BY POWDER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL BIVALIRUDIN MARKET SIZE, BY POWDER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL BIVALIRUDIN MARKET SIZE, BY ANGIOPLASTY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL BIVALIRUDIN MARKET SIZE, BY ANGIOPLASTY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL BIVALIRUDIN MARKET SIZE, BY HEPARIN-INDUCED THROMBOCYTOPENIA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL BIVALIRUDIN MARKET SIZE, BY HEPARIN-INDUCED THROMBOCYTOPENIA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL BIVALIRUDIN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL BIVALIRUDIN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL BIVALIRUDIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL BIVALIRUDIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL BIVALIRUDIN MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL BIVALIRUDIN MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL BIVALIRUDIN MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL BIVALIRUDIN MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. AMERICAS BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 30. AMERICAS BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 31. AMERICAS BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 32. AMERICAS BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 33. AMERICAS BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 34. AMERICAS BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 35. AMERICAS BIVALIRUDIN MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 36. AMERICAS BIVALIRUDIN MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 37. ARGENTINA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 38. ARGENTINA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 39. ARGENTINA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 40. ARGENTINA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 41. ARGENTINA BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 42. ARGENTINA BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 43. BRAZIL BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 44. BRAZIL BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 45. BRAZIL BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 46. BRAZIL BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 47. BRAZIL BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 48. BRAZIL BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 49. CANADA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 50. CANADA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 51. CANADA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 52. CANADA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 53. CANADA BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 54. CANADA BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 55. MEXICO BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 56. MEXICO BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 57. MEXICO BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 58. MEXICO BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 59. MEXICO BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 60. MEXICO BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 61. UNITED STATES BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 62. UNITED STATES BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 63. UNITED STATES BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 64. UNITED STATES BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 65. UNITED STATES BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 66. UNITED STATES BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 67. UNITED STATES BIVALIRUDIN MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 68. UNITED STATES BIVALIRUDIN MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC BIVALIRUDIN MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC BIVALIRUDIN MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 77. AUSTRALIA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 78. AUSTRALIA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 79. AUSTRALIA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 80. AUSTRALIA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 81. AUSTRALIA BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 82. AUSTRALIA BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 83. CHINA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 84. CHINA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 85. CHINA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 86. CHINA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 87. CHINA BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 88. CHINA BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 89. INDIA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 90. INDIA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 91. INDIA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 92. INDIA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 93. INDIA BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 94. INDIA BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 95. INDONESIA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 96. INDONESIA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 97. INDONESIA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 98. INDONESIA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 99. INDONESIA BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 100. INDONESIA BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 101. JAPAN BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 102. JAPAN BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 103. JAPAN BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 104. JAPAN BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 105. JAPAN BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 106. JAPAN BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 107. MALAYSIA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 108. MALAYSIA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 109. MALAYSIA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 110. MALAYSIA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 111. MALAYSIA BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 112. MALAYSIA BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 113. PHILIPPINES BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 114. PHILIPPINES BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 115. PHILIPPINES BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 116. PHILIPPINES BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 117. PHILIPPINES BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 118. PHILIPPINES BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 119. SINGAPORE BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 120. SINGAPORE BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 121. SINGAPORE BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 122. SINGAPORE BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 123. SINGAPORE BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 124. SINGAPORE BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 125. SOUTH KOREA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 126. SOUTH KOREA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 127. SOUTH KOREA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 128. SOUTH KOREA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 129. SOUTH KOREA BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 130. SOUTH KOREA BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 131. TAIWAN BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 132. TAIWAN BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 133. TAIWAN BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 134. TAIWAN BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 135. TAIWAN BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 136. TAIWAN BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 137. THAILAND BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 138. THAILAND BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 139. THAILAND BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 140. THAILAND BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 141. THAILAND BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 142. THAILAND BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 143. VIETNAM BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 144. VIETNAM BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 145. VIETNAM BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 146. VIETNAM BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 147. VIETNAM BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 148. VIETNAM BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA BIVALIRUDIN MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA BIVALIRUDIN MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 157. DENMARK BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 158. DENMARK BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 159. DENMARK BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 160. DENMARK BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 161. DENMARK BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 162. DENMARK BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 163. EGYPT BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 164. EGYPT BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 165. EGYPT BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 166. EGYPT BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 167. EGYPT BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 168. EGYPT BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 169. FINLAND BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 170. FINLAND BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 171. FINLAND BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 172. FINLAND BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 173. FINLAND BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 174. FINLAND BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 175. FRANCE BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 176. FRANCE BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 177. FRANCE BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 178. FRANCE BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 179. FRANCE BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 180. FRANCE BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 181. GERMANY BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 182. GERMANY BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 183. GERMANY BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 184. GERMANY BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 185. GERMANY BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 186. GERMANY BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 187. ISRAEL BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 188. ISRAEL BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 189. ISRAEL BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 190. ISRAEL BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 191. ISRAEL BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 192. ISRAEL BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 193. ITALY BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 194. ITALY BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 195. ITALY BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 196. ITALY BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 197. ITALY BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 198. ITALY BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 199. NETHERLANDS BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 200. NETHERLANDS BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 201. NETHERLANDS BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 202. NETHERLANDS BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 203. NETHERLANDS BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 204. NETHERLANDS BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 205. NIGERIA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 206. NIGERIA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 207. NIGERIA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 208. NIGERIA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 209. NIGERIA BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 210. NIGERIA BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 211. NORWAY BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 212. NORWAY BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 213. NORWAY BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 214. NORWAY BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 215. NORWAY BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 216. NORWAY BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 217. POLAND BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 218. POLAND BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 219. POLAND BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 220. POLAND BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 221. POLAND BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 222. POLAND BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 223. QATAR BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 224. QATAR BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 225. QATAR BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 226. QATAR BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 227. QATAR BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 228. QATAR BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 229. RUSSIA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 230. RUSSIA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 231. RUSSIA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 232. RUSSIA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 233. RUSSIA BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 234. RUSSIA BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 235. SAUDI ARABIA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 236. SAUDI ARABIA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 237. SAUDI ARABIA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 238. SAUDI ARABIA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 239. SAUDI ARABIA BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 240. SAUDI ARABIA BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 241. SOUTH AFRICA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 242. SOUTH AFRICA BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 243. SOUTH AFRICA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 244. SOUTH AFRICA BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 245. SOUTH AFRICA BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 246. SOUTH AFRICA BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 247. SPAIN BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 248. SPAIN BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 249. SPAIN BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 250. SPAIN BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 251. SPAIN BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 252. SPAIN BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 253. SWEDEN BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 254. SWEDEN BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 255. SWEDEN BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 256. SWEDEN BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 257. SWEDEN BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 258. SWEDEN BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 259. SWITZERLAND BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 260. SWITZERLAND BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 261. SWITZERLAND BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 262. SWITZERLAND BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 263. SWITZERLAND BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 264. SWITZERLAND BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 265. TURKEY BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 266. TURKEY BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 267. TURKEY BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 268. TURKEY BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 269. TURKEY BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 270. TURKEY BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 271. UNITED ARAB EMIRATES BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 272. UNITED ARAB EMIRATES BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 273. UNITED ARAB EMIRATES BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 274. UNITED ARAB EMIRATES BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 275. UNITED ARAB EMIRATES BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 276. UNITED ARAB EMIRATES BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 277. UNITED KINGDOM BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2018-2023 (USD MILLION)
  • TABLE 278. UNITED KINGDOM BIVALIRUDIN MARKET SIZE, BY DOSAGE FORM, 2024-2030 (USD MILLION)
  • TABLE 279. UNITED KINGDOM BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 280. UNITED KINGDOM BIVALIRUDIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 281. UNITED KINGDOM BIVALIRUDIN MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 282. UNITED KINGDOM BIVALIRUDIN MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 283. BIVALIRUDIN MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 284. BIVALIRUDIN MARKET, FPNV POSITIONING MATRIX, 2023